For example, CTLA-4 inhibitors are associated with higher rates of gastrointestinal effects and adrenal disorders, while PD-1/PD-L1 inhibitors are more associated with hypothyroidism and pneumonitis [2,14]. This evidence concerns the gene CD274 and hypothyroidism.